Log in

NYSE:NVRONevro Stock Price, Forecast & News

+0.89 (+0.71 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $126.49
50-Day Range
MA: $119.25
52-Week Range
Now: $126.49
Volume248,870 shs
Average Volume519,140 shs
Market Capitalization$4.30 billion
P/E RatioN/A
Dividend YieldN/A
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Read More
Nevro logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments



Sales & Book Value

Annual Sales$390.26 million
Book Value$6.98 per share


Net Income$-103,690,000.00


Market Cap$4.30 billion
Next Earnings Date8/13/2020 (Estimated)

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Nevro (NYSE:NVRO) Frequently Asked Questions

How has Nevro's stock been impacted by COVID-19 (Coronavirus)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 15.2% and is now trading at $126.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nevro?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nevro.

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) posted its quarterly earnings data on Tuesday, May, 5th. The medical equipment provider reported ($0.78) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.99) by $0.21. The medical equipment provider earned $87.47 million during the quarter, compared to analyst estimates of $86.70 million. Nevro had a negative return on equity of 40.67% and a negative net margin of 21.36%. Nevro's revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period last year, the company earned ($1.45) EPS. View Nevro's earnings history.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $86.4-86.9 million, compared to the consensus revenue estimate of $96.96 million.

What price target have analysts set for NVRO?

12 brokers have issued 1-year price objectives for Nevro's shares. Their forecasts range from $65.00 to $158.00. On average, they anticipate Nevro's stock price to reach $115.33 in the next year. This suggests that the stock has a possible downside of 8.8%. View analysts' price targets for Nevro.

Has Nevro been receiving favorable news coverage?

News headlines about NVRO stock have been trending very positive on Tuesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nevro earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNevro.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.29%), Fred Alger Management LLC (5.83%), Invesco Ltd. (4.17%), Franklin Resources Inc. (3.64%), Perceptive Advisors LLC (3.21%) and Lord Abbett & CO. LLC (2.28%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle and Shawn Mccormick. View institutional ownership trends for Nevro.

Which major investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Balyasny Asset Management LLC, ArrowMark Colorado Holdings LLC, Franklin Resources Inc., Federated Hermes Inc., Nuveen Asset Management LLC, Engineers Gate Manager LP, and Invesco Ltd.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, and Shawn Mccormick. View insider buying and selling activity for Nevro.

Which major investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Lord Abbett & CO. LLC, Two Sigma Advisers LP, Castleark Management LLC, Fred Alger Management LLC, Rock Springs Capital Management LP, and Deutsche Bank AG. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle. View insider buying and selling activity for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $126.49.

How big of a company is Nevro?

Nevro has a market capitalization of $4.30 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.